KRAS and neoplasm: In this latter tumor, we have found that ACKR2 expression is downregulated in more aggressive tumors by the activation of the KRAS/BRAF/ERK pathway, thus unleashing chemokine-mediated macrophage recruitment and their acquisition of an M2-like phenotype that sustains angiogenesis and tumor growth (52, 53).